Peroxisome proliferator-activated receptor-γ activity is associated with renal microvasculature

American Journal of Physiology - Renal Physiology

Volumn 281, Issue 6 50-6, 2001, Pages

  Guan, Youfei ^a   Zhang, Yahua ^a   Schneider, André ^a   Davis, Linda ^a   Breyer, Richard M ^b   Breyer, Matthew D ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipocyte fatty acid binding protein; Glomeruli; Mesangial cell

Indexed keywords

DELTA12 PROSTAGLANDIN J2; FATTY ACID BINDING PROTEIN; ISOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TROGLITAZONE;

ADIPOCYTE; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; GENE EXPRESSION; GLOMERULOPATHY; GLOMERULUS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY BLOOD VESSEL; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RABBIT; TISSUE DISTRIBUTION;

EID: 0035658541     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.0025.2001     Document Type: Article

References (45)

1. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
2. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation
3. PPARγ, the ultimate thrifty gene
4. Human adipocyte lipid-binding protein: Purification of the protein and cloning of its complementary DNA
5. Expression of specific mRNAs during adipose differentiation: Identification of an mRNA encoding a homologue of myelin P2 protein
6. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
7. Antidiabetic drugs present and future: Will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
8. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas
9. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2
10. The organization, promoter analysis, and expression of the human PPARγ gene
11. PPARγ3 MRNA: A distinct PPARγ mRNA subtype transcribed from an independent promoter
12. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
13. 2 is a ligand for the adipocyte determination factor PPAR-gamma
14. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats
15. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping
16. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death
17. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans
18. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma
19. Adipocyte P2 gene: Developmental expression and homology of 5'-flanking sequences among fat cell-specific genes
20. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
21. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
22. PPARγ agonists inhibit production of monocyte inflammatory cytokines
23. Lipid-binding proteins in rat and human kidney
24. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
25. 2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: Evidence from biochemical measurements and inhibitor trials
26. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review
27. Troglitazone halts diabetic glomerulo-sclerosis by blockade of mesangial expansion
28. Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions
29. PPAR-gamma agonists: Therapeutic role in diabetes, inflammation and cancer
30. PPARgamma and the treatment of insulin resistance
31. Evidence for the presence of smooth muscle α-actin within pericytes of the renal medulla
32. PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes
33. Structural properties of the adipocyte lipid binding protein
34. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
35. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
36. Differentiation-dependent expression of heart type fatty acid-binding protein in C2C12 muscle cells
37. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells
38. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
39. Mammary derived growth inhibitor is not a distinct protein but a mix of heart-type and adipocyte-type fatty acid-binding protein
40. The fatty acid transport function of fatty acid-binding proteins
41. Cytosolic and nuclear distribution of PPARgamma2 in differentiating 3T3-L1 preadipocytes
42. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer
43. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney
44. Members of the fatty acid binding protein family are differentiation factors for the mammary gland
45. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats